EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD : A Prospective Study

Federica Tavaglione iD, Maral Amangurbanova iD, Alexander H Yang, Monica A Tincopa iD, Veeral Ajmera iD, Lisa Richards, Christian Butcher, Christie Hernandez, Egbert Madamba, Seema Singh, Ricki Bettencourt, Claude B Sirlin und 1 weitere

Alimentary Pharmacology & Therapeutics · 2025-03 · 61 (6) · 1043-1054

DOI: 10.1111/apt.18506 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 17.01.2025. Verfasst von Federica Tavaglione und 12 weiteren Autor:innen. Beteiligte Einrichtung: MASLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Glycerophospholipids, Fatty Liver, Liver Diseases, Alcoholic. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIDDK NIH HHS, NIAAA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The current subclassification of steatotic liver disease (SLD) relies on validated questionnaires, such as Alcohol Use Disorders Identification Test (AUDIT) and Lifetime Drinking History (LDH), which, while useful, are impractical and lack precision for their use in routine clinical practice. Phosphatidylethanol (PEth) is a quantitative, objective alcohol biomarker with high sensitivity and specificity.

Aims

To assess the diagnostic accuracy of PEth for differentiating metabolic dysfunction and alcohol‐associated liver disease (MetALD) from metabolic dysfunction‐associated steatotic liver disease (MASLD) in a large, population‐based, prospective, multiethnic cohort of individuals with overweight or obesity.

Methods

This is a cross‐sectional analysis of a prospective study including 374 adults with overweight or obesity residing in Southern California who had SLD as defined by MRI‐PDFF ≥ 5%. The clinical research visit included medical history, biochemical and PEth testing, standardised validated questionnaires (including AUDIT and LDH), physical examination, and advanced imaging using MRI‐PDFF and MRE.

Results

Among 374 adults with SLD, the prevalence of MASLD, MetALD, and ALD was 90.1%, 6.4%, and 3.5%, respectively. PEth had a robust diagnostic accuracy in the detection of MetALD (AUROC 0.81, 95%CI 0.73–0.89) and the Youden cut‐off was 25 ng/mL. In head‐to‐head comparative efficacy analysis, PEth was both statistically and clinically superior to all previously used indirect alcohol biomarkers for diagnosing MetALD, including aspartate aminotransferase/alanine aminotransferase ratio, mean corpuscular volume, gamma glutamyltransferase, and ALD/NAFLD index ( p < 0.05).

Conclusions

PEth outperforms previously used non‐invasive tests in differentiating MetALD from MASLD and has the potential to change clinical practice by enhancing the subclassification of SLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlycerophospholipidsFatty LiverLiver Diseases, AlcoholicHumansBiomarkersMaleProspective StudiesFemaleMiddle AgedCross-Sectional StudiesAdultCaliforniaSensitivity and SpecificityAgedDiagnosis, DifferentialObesityAlcohol Drinking

Stichwörter der Autor:innen

ALDNAFLDSLDalcoholbiomarkers

Substanzen

phosphatidylethanolGlycerophospholipidsBiomarkers

Autor:innen und Institutionen

  • MASLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, USA.
  • Liver Imaging Group, Department of Radiology, University of California at San Diego, La Jolla, California, USA.
  • School of Public Health, University of California at San Diego, La Jolla, California, USA.

ORCID-Profile: Federica Tavaglione, Maral Amangurbanova, Monica A Tincopa, Veeral Ajmera, Rohit Loomba

Förderung

  • NCATS NIH HHS
  • NIDDK NIH HHS
  • NIAAA NIH HHS
  • NHLBI NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Heart, Lung, and Blood Institute
  • National Center for Advancing Translational Sciences
  • National Institute on Alcohol Abuse and Alcoholism

Zitieren

APA

Tavaglione, F., Amangurbanova, M., Yang, A. H., Tincopa, M. A., Ajmera, V., Richards, L., Butcher, C., Hernandez, C., Madamba, E., Singh, S., Bettencourt, R., Sirlin, C. B., & Loomba, R. (2025). Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD : A Prospective Study. Alimentary Pharmacology & Therapeutics, 61(6), 1043-1054. https://doi.org/10.1111/apt.18506

Vancouver

Tavaglione F, Amangurbanova M, Yang AH, Tincopa MA, Ajmera V, Richards L, et al. Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD : A Prospective Study. Alimentary Pharmacology & Therapeutics. 2025;61(6):1043-1054. doi:10.1111/apt.18506

BibTeX
@article{Tavaglione2025,
  author = {Tavaglione, Federica and Amangurbanova, Maral and Yang, Alexander H and Tincopa, Monica A and Ajmera, Veeral and Richards, Lisa and Butcher, Christian and Hernandez, Christie and Madamba, Egbert and Singh, Seema and Bettencourt, Ricki and Sirlin, Claude B and Loomba, Rohit},
  title = {Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD : A Prospective Study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  volume = {61},
  number = {6},
  pages = {1043--1054},
  doi = {10.1111/apt.18506}
}
Kostenlos starten →